AKT1 and mantle cell lymphoma: Through activity-based protein profiling (ABPP) and cell-based drug screening in MCL cell lines followed by validation in ibrutinib-resistant MCL human samples, it was demonstrated that ibrutinib-resistant MCL cells are characterized by activation of the PI3K-AKT-motR pathway and overexpression of integrin-β1, which can facilitate adhesion to stroma cells and clonogenic growth in the presence of ibrutinib [71].